Main Article Content
Dr Batool Butt
Dr Muhammad Farhan
Dr Hajra Mateen
Dr Asim Shehzad
Zaghum Abbas
Sana Afzal
Keywords
Rosuvastatin, Acute kidney injury, chronic kidney disease, Contrast induced nephropathy (CIN).
Abstract
Objectives: To evaluate the effectiveness of rosuvastatin in reducing the incidence of contrast-induced acute kidney injury (CI-AKI) in patients with chronic kidney disease (CKD).
Materials and Methods: This Cross sectional study is conducted at multiple centers including Mercy Teaching Hospital Peshawar, Pakistan and Islam Medical College Sialkot, Pakistan in the duration from December, 2023 to May, 2024. A total of 130 patients who met the selection criteria were enrolled in the study, each receiving a unique identification number. Detail clinical and physical examinations were conducted for all participants. Blood samples were collected, and creatinine levels were measured at 48 and 72 hours post-percutaneous coronary intervention (PCI) to assess for contrast-induced nephropathy (CIN) and evaluate the therapy's efficacy according to the operational definition. All procedures were carried out by an experienced surgical team to ensure consistent and reliable patient management and assessment. Data was collected by using a pre-designed questionnaire.
Results: The mean age of the patients was 47.85 ± 8.47 years, with a gender distribution of 75 males (57.7%) and 55 females (42.3%). Mean serum creatinine levels was 0.83 ± 0.18 mg/dL at 48 hours and 0.90 ± 0.21 mg/dL at 72 hours post-contrast exposure. The mean duration of chronic kidney disease was 7.32 ± 1.52 months. Rosuvastatin therapy was effective in 105 (80.8%) patients. On stratification of confounders and effect modifiers in relation to efficacy, no significant differences were observed across age groups (P=0.96), gender (P=0.79), and the duration of CKD (P=0.34). However, a significant difference was found in relation to serum creatinine levels (P=0.04).
Conclusion: It was concluded that rosuvastatin therapy significantly reduces the incidence of CI-AKI in CKD patients, likely due to its anti-inflammatory and antioxidative properties. Further research is needed to optimize dosing and identify which patient subgroups benefit most.
References
1.Chandiramani R, Cao D, Nicolas J, Mehran R. Contrast-induced acute kidney injury. Cardiovascular intervention and therapeutics. 2020;35:209-17.
2.Chalikias G, Drosos I, Tziakas DN. Contrast-induced acute kidney injury: an update. Cardiovascular drugs and therapy. 2016;30:215-28.
3.McCullough PA. Multimodality prevention of contrast-induced acute kidney injury. American Journal of Kidney Diseases. 2008;51(2):169-72.
4.Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG‐CoA reductase inhibitor. Cardiovascular drug reviews. 2002;20(4):303-28.
5.Kitzler TM, Jaberi A, Sendlhofer G, Rehak P, Binder C, Petnehazy E, et al. Efficacy of vitamin E and N-acetylcysteine in the prevention of contrast induced kidney injury in patients with chronic kidney disease: a double blind, randomized controlled trial. Wien Klin Wochenschr. 2012;124(9-10):312-9.
6.Hadjiphilippou S, Ray KK. Cholesterol-lowering agents: statins—for everyone? Circulation research. 2019;124(3):354-63.
7.Lim H-S, Tonino PA, De Bruyne B, Yong AS, Lee B-K, Pijls NH, et al. The impact of age on fractional flow reserve-guided percutaneous coronary intervention: a FAME (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) trial substudy. International journal of cardiology. 2014;177(1):66-70.
8.Lee J, Cho JY, Lee HJ, Jeong YY, Kim CK, Park BK, et al. Contrast-induced nephropathy in patients undergoing intravenous contrast-enhanced computed tomography in Korea: a multi-institutional study in 101487 patients. Korean journal of radiology. 2014;15(4):456-63.
9.Lee Y-C, Hsieh C-C, Chang T-T, Li C-Y. Contrast-induced acute kidney injury among patients with chronic kidney disease undergoing imaging studies: a meta-analysis. American Journal of Roentgenology. 2019;213(4):728-35.
10.Asadullah BD, Kumar S, Junejo AM, Memon R, Lal O. Rosuvastatin Therapy in Prevention of Contrast-Induced Acute Kidney Injury in Patients with Chronic Kidney Disease. Pakistan Journal of Medical & Health Sciences. 2023;17(05):216-.
11.Alpert MA. Do statins reduce the risk of contrast-induced acute kidney injury in patients undergoing coronary angiography or percutaneous coronary interventions? : American College of Cardiology Foundation Washington, DC; 2014. p. 80-2.
12.Azhar F, Saeed R, Danish S, Anwar S. Prevalence and burden of chronic kidney disease in developing countries: a review. Asian J Pediatr Nephrol. 2021;4:11-7.
13.Leoncini M, Toso A, Maioli M, Tropeano F, Badia T, Villani S, et al. Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study. American Heart Journal. 2014;168(5):792-7.
14.Abaci O, Ozkan AA, Kocas C, Cetinkal G, Karaca OS, Baydar O, et al. Impact of rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography. The American Journal of Cardiology. 2015;115(7):867-71.
15.Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. Journal of the American College of Cardiology. 2014;63(1):62-70.
16.Zhang J, Guo Y, Jin Q, Bian L, Lin P. Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury. Drug Design, Development and Therapy. 2018:3685-90.
17.Ukaigwe A, Karmacharya P, Mahmood M, Pathak R, Aryal MR, Jalota L, et al. Meta-analysis on efficacy of statins for prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography. The American journal of cardiology. 2014;114(9):1295-302.
